93 related articles for article (PubMed ID: 23831394)
1. L-165,041, troglitazone and their combination treatment to attenuate high glucose-induced receptor for advanced glycation end products (RAGE) expression.
Liang YJ; Jian JH; Chen CY; Hsu CY; Shih CY; Leu JG
Eur J Pharmacol; 2013 Sep; 715(1-3):33-8. PubMed ID: 23831394
[TBL] [Abstract][Full Text] [Related]
2. Advanced glycation end products-induced apoptosis attenuated by PPARdelta activation and epigallocatechin gallate through NF-kappaB pathway in human embryonic kidney cells and human mesangial cells.
Liang YJ; Jian JH; Liu YC; Juang SJ; Shyu KG; Lai LP; Wang BW; Leu JG
Diabetes Metab Res Rev; 2010 Jul; 26(5):406-16. PubMed ID: 20583309
[TBL] [Abstract][Full Text] [Related]
3. Peroxisome proliferator-activated receptor δ downregulates the expression of the receptor for advanced glycation end products and pro-inflammatory cytokines in the kidney of streptozotocin-induced diabetic mice.
Liang YJ; Chen SA; Jian JH
Eur J Pharm Sci; 2011 May; 43(1-2):65-70. PubMed ID: 21458563
[TBL] [Abstract][Full Text] [Related]
4. Differential modulation of COX-2 expression in A549 airway epithelial cells by structurally distinct PPAR(gamma) agonists: evidence for disparate functional effects which are independent of NF-(kappa)B and PPAR(gamma).
Patel KM; Wright KL; Whittaker P; Chakravarty P; Watson ML; Ward SG
Cell Signal; 2005 Sep; 17(9):1098-110. PubMed ID: 15993751
[TBL] [Abstract][Full Text] [Related]
5. Peroxisome proliferator-activated receptor γ agonist troglitazone inhibits high mobility group box 1 expression in endothelial cells via suppressing transcriptional activity of nuclear factor κB and activator protein 1.
Gao M; Hu Z; Zheng Y; Zeng Y; Shen X; Zhong D; He F
Shock; 2011 Sep; 36(3):228-34. PubMed ID: 21617575
[TBL] [Abstract][Full Text] [Related]
6. The effect of PPARγ agonist on SGLT2 and glucagon expressions in alpha cells under hyperglycemia.
Kim M; Lee EJ; Shin HM; Jung HS; Kim TK; Kim TN; Kwon MJ; Lee SH; Rhee BD; Park JH
J Endocrinol Invest; 2017 Oct; 40(10):1069-1076. PubMed ID: 28391584
[TBL] [Abstract][Full Text] [Related]
7. Glucagon-like peptide receptor agonists attenuate advanced glycation end products-induced inflammation in rat mesangial cells.
Chang JT; Liang YJ; Hsu CY; Chen CY; Chen PJ; Yang YF; Chen YL; Pei D; Chang JB; Leu JG
BMC Pharmacol Toxicol; 2017 Oct; 18(1):67. PubMed ID: 29065926
[TBL] [Abstract][Full Text] [Related]
8. Nifedipine inhibits advanced glycation end products (AGEs) and their receptor (RAGE) interaction-mediated proximal tubular cell injury via peroxisome proliferator-activated receptor-gamma activation.
Matsui T; Yamagishi S; Takeuchi M; Ueda S; Fukami K; Okuda S
Biochem Biophys Res Commun; 2010 Jul; 398(2):326-30. PubMed ID: 20599709
[TBL] [Abstract][Full Text] [Related]
9. Peroxisome proliferator-activated receptor gamma down-regulates receptor for advanced glycation end products and inhibits smooth muscle cell proliferation in a diabetic and nondiabetic rat carotid artery injury model.
Wang K; Zhou Z; Zhang M; Fan L; Forudi F; Zhou X; Qu W; Lincoff AM; Schmidt AM; Topol EJ; Penn MS
J Pharmacol Exp Ther; 2006 Apr; 317(1):37-43. PubMed ID: 16368901
[TBL] [Abstract][Full Text] [Related]
10. Suppression of NF-kappaB and GSK-3beta is involved in colon cancer cell growth inhibition by the PPAR agonist troglitazone.
Ban JO; Kwak DH; Oh JH; Park EJ; Cho MC; Song HS; Song MJ; Han SB; Moon DC; Kang KW; Hong JT
Chem Biol Interact; 2010 Oct; 188(1):75-85. PubMed ID: 20540935
[TBL] [Abstract][Full Text] [Related]
11. Troglitazone suppresses the secretion of type I collagen by mesangial cells in vitro.
Routh RE; Johnson JH; McCarthy KJ
Kidney Int; 2002 Apr; 61(4):1365-76. PubMed ID: 11918743
[TBL] [Abstract][Full Text] [Related]
12. Pioglitazone inhibits high glucose-induced expression of receptor for advanced glycation end products in coronary artery smooth muscle cells.
Di BB; Li HW; Li WP; Shen XH; Sun ZJ; Wu X
Mol Med Rep; 2015 Apr; 11(4):2601-7. PubMed ID: 25523934
[TBL] [Abstract][Full Text] [Related]
13. Troglitazone inhibits synthesis of transforming growth factor-beta1 and reduces matrix production in human peritoneal mesothelial cells.
Peng Y; Liu H; Liu F; Liu Y; Li J; Chen X
Nephrology (Carlton); 2006 Dec; 11(6):516-23. PubMed ID: 17199790
[TBL] [Abstract][Full Text] [Related]
14. Nifedipine, a calcium channel blocker, inhibits advanced glycation end product (AGE)-elicited mesangial cell damage by suppressing AGE receptor (RAGE) expression via peroxisome proliferator-activated receptor-gamma activation.
Matsui T; Yamagishi S; Takeuchi M; Ueda S; Fukami K; Okuda S
Biochem Biophys Res Commun; 2009 Jul; 385(2):269-72. PubMed ID: 19460355
[TBL] [Abstract][Full Text] [Related]
15. Peroxisome proliferator-activated receptor γ ligands retard cultured vascular smooth muscle cells calcification induced by high glucose.
Zhou YB; Zhang J; Peng DQ; Chang JR; Cai Y; Yu YR; Jia MZ; Wu W; Guan YF; Tang CS; Qi YF
Cell Biochem Biophys; 2013 Jul; 66(3):421-9. PubMed ID: 23274912
[TBL] [Abstract][Full Text] [Related]
16. Effect of troglitazone on tumor necrosis factor alpha and transforming growth factor beta expression and action in human adipocyte precursor cells in primary culture.
Skurk T; Birgel M; Lee YM; Hauner H
Metabolism; 2006 Mar; 55(3):309-16. PubMed ID: 16483873
[TBL] [Abstract][Full Text] [Related]
17. Peroxisome proliferator-activated receptor gamma ligands induce cell cycle arrest and apoptosis in human renal carcinoma cell lines.
Yang FG; Zhang ZW; Xin DQ; Shi CJ; Wu JP; Guo YL; Guan YF
Acta Pharmacol Sin; 2005 Jun; 26(6):753-61. PubMed ID: 15916743
[TBL] [Abstract][Full Text] [Related]
18. Peroxisome proliferator-activated receptor-gamma activation attenuates cardiac fibrosis in type 2 diabetic rats: the effect of rosiglitazone on myocardial expression of receptor for advanced glycation end products and of connective tissue growth factor.
Ihm SH; Chang K; Kim HY; Baek SH; Youn HJ; Seung KB; Kim JH
Basic Res Cardiol; 2010 May; 105(3):399-407. PubMed ID: 19902320
[TBL] [Abstract][Full Text] [Related]
19. Comparison of cytokine modulation by natural peroxisome proliferator-activated receptor gamma ligands with synthetic ligands in intestinal-like Caco-2 cells and human dendritic cells--potential for dietary modulation of peroxisome proliferator-activated receptor gamma in intestinal inflammation.
Marion-Letellier R; Butler M; Déchelotte P; Playford RJ; Ghosh S
Am J Clin Nutr; 2008 Apr; 87(4):939-48. PubMed ID: 18400717
[TBL] [Abstract][Full Text] [Related]
20. Keratinocyte-derived vascular endothelial growth factor biosynthesis represents a pleiotropic side effect of peroxisome proliferator-activated receptor-gamma agonist troglitazone but not rosiglitazone and involves activation of p38 mitogen-activated protein kinase: implications for diabetes-impaired skin repair.
Schiefelbein D; Seitz O; Goren I; Dissmann JP; Schmidt H; Bachmann M; Sader R; Geisslinger G; Pfeilschifter J; Frank S
Mol Pharmacol; 2008 Oct; 74(4):952-63. PubMed ID: 18599600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
